On August 3, 2026, the Department of Homeland Security, as Chair of the Forced Labor Enforcement Task Force (FLETF), published an updated UFLPA Entity List adding 43 new entities (two of which appear on two separate sub-lists) and making technical corrections to two existing entries. The consolidated list now stands at 187 entities. Goods mined, produced, or manufactured, wholly or in part, by a listed entity are subject to the UFLPA's rebuttable presumption of forced labor and are prohibited from entry under 19 U.S.C. § 1307, effective immediately upon listing.

Discover financing strategies for Saudi Arabia's data center build-out, from bankability and project finance to capital structuring and debt advisory.

Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.

Enterprise Management Incentive (EMI) option plans have been at the centre of UK employee incentivisation for many years and remain popular with privately owned, fast-growing companies.